Evotec Q2 Earnings Call Highlights
Evotec said unfavorable FX will cut first-half revenue by about €13 million. It guided Q2 adjusted group EBITDA to about -€20.8 million and -€42.7 million for 1H 2026. Full-year 2026 revenue is now ~€570m-€610m (inc. FX) and adjusted EBITDA -€70m to -€105m. Liquidity rose to €465.6m.
How this was made
The 30-second read
Why it matters
Evotec guided to lower 2026 revenue and a wider negative adjusted EBITDA range, primarily due to delayed recognition from existing strategic partnerships, slower formation of new partnerships, and slower sales-to-revenue conversion timing. The company also highlighted improved commercial indicators in the base D&PD business, ongoing strategic partnership pipeline activity, higher liquidity, and a cost-savings program expected to deliver run-rate savings by end-2027 with partial realization in 2026.
Market read
The guidance cut is a direct earnings and valuation catalyst, with quantified drivers and near-term liquidity/cost-savings offsets that affect how traders model 2026 downside versus 2027 catch-up.
What to watch
Liquidity increased to €465.6m and Horizon run-rate savings are expected to start showing in 2H 2026, which could cushion the earnings trajectory despite the EBITDA reset.
Background
The piece summarizes Evotec’s Q2 earnings call, focusing on a full-year 2026 outlook reduction and the operational reasons behind it.
Ticker impact
Evotec cut 2026 revenue and EBITDA outlook, citing delayed strategic-partner revenue, slower new deals, and weaker sales-to-revenue conversion timing.
Downward bias for near-term sentiment and valuation multiples, with potential stabilization if investors focus on 2027 catch-up and 2026 cost-savings ramp.
The article provides specific revised 2026 revenue and adjusted EBITDA ranges, plus quantified drivers (40% delayed, 45% slower new partnerships, 15% conversion timing) and liquidity/cost-savings updates that frame downside risk and partial offsets.
Market effects
Drug-discovery services peers may face read-across on how strategic partnership revenue timing and conversion delays affect 2026 margins.
Limited direct regional spillover, but European biotech services sentiment could soften given the guidance cut.
Global biotech services investors may reprice partnership-driven revenue models and fixed-cost leverage.
Counterpoint
Investors may treat the revenue shortfall as timing-only, with delayed strategic-partner revenues expected in 2027 and cost savings ramping in 2H 2026.
Key entities
- companyEvotec SE
Guided down 2026 revenue and adjusted EBITDA, attributing the change to partnership revenue timing, slower new deal contributions, and conversion delays; also reported liquidity and cost-savings progress.
- companyGilead
Acquisition of EVOequity portfolio company Tubulis generated gross proceeds of about $100m cited as a driver of higher Evotec liquidity.
- companyBristol Myers Squibb
Evotec described the collaboration as very healthy and expects it to return to growth next year, framing 2026 as a transition year.
